- Home
- EOI vs KURA Comparison
EOI vs KURA Comparison
Compare EOI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EOI
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | EOI | KURA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.1M | 765.8M |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EOI | KURA |
|---|---|---|
| Price | $19.86 | $9.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 110.8K | ★ 1.4M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $25.83 |
| Revenue Next Year | N/A | $103.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $17.06 | $5.45 |
| 52 Week High | $21.58 | $12.49 |
Technical Indicators
Market Signals| Indicator | EOI | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 66.74 |
| Support Level | $19.37 | $9.68 |
| Resistance Level | $20.90 | $10.50 |
| Average True Range (ATR) | 0.32 | 0.42 |
| MACD | 0.13 | 0.13 |
| Stochastic Oscillator | 84.46 | 85.20 |
Price Performance
Historical ComparisonAbout EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.